The key point is whether the VITT/TTS was observed with ChAdOx1 nCoV-19 and AD26.COV2·S vaccinations to represent side effects specific to adenovirus vector vaccines and the extent to which this may ...

A nasal vaccine for COVID-19—based on technology developed at Washington University in St. Louis—is poised to enter a phase 1 ...

The adenovirus carries the SARS-CoV-2 protein into the nose, enabling people to mount an immune defense against the SARS-CoV-2 virus without becoming sick. “It is gratifying to see the vaccine that we ...

While Robert F. Kennedy Jr., President Donald Trump’s pick to lead the US Department of Health and Human Services, has backpedaled on his anti-vaccine rhetoric during his Senate confirmation ...

Yet, uptake levels of vaccines in the US would tell a different story. As of mid-December, only 20.9 percent of adults in the ...

Dendritic cell (DC)-based vaccines have emerged as a promising strategy in cancer ... we have developed a polymeric nanocomplex incorporating (1) oncolytic adenovirus (oAd) co-expressing interleukin ...

Other vaccine types (eg, mRNA, viral vector or protein subunit type) need to be studied for validation, ideally prospectively and with multicentre collaboration. In conclusion, this study suggests ...